This information is intended for UK healthcare professionals only. Prescribing Information can be found at the bottom of the page. This information is intended to be viewed on a standard desktop computer.

teva

Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva online, or tel: 0207 540 7117 or email: medinfo@tevauk.com.

 

About Braltus® (tiotropium)

Braltus_image1.png

Braltus® is indicated:1

  • as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD)
  • for use in adults

The contents of one Braltus® capsule should be taken once daily, with the Zonda® inhaler.

Braltus® has a delivered dose of 10 micrograms of tiotropium which is the same as Spiriva® HandiHaler® (tiotropium).

A treatment and device combination that in real life…2

  • 96% of COPD patients found Braltus® easy or very easy to use*
  • 95% of COPD patients felt confident or very confident using Braltus®**
  • 84% of COPD patients find the clear capsules to be beneficial or very beneficial
  • 100% of COPD patients find that using Braltus® fits easily into their daily routine

COPD: Chronic obstructive pulmonary disease

*100 patients with COPD who were switched to Braltus® and had received Braltus® for an average of 16.5 months, were asked “How easy or difficult do you find it to use your current inhaler, Braltus® day-to-day?”. 4% of patients stated that they found Braltus® either Difficult or Very difficult to use.2

**100 patients with COPD who were switched to Braltus® and had received Braltus® for an average of 16.5 months, were asked “Following instruction and guidance from your healthcare professional, how confident did you feel about using the Braltus® device?”. 5% of patients did not feel confident about using Braltus®.2

100 patients with COPD who were switched to Braltus® and had received Braltus® for an average of 16.5 months, were asked “To what extent do you find Braltus® clear capsule beneficial?”. 16% of patients found the clear capsules neither beneficial nor unbeneficial or not beneficial.2

††100 patients with COPD who were switched to Braltus® and had received Braltus® for an average of 16.5 months, were asked “To what extent does Braltus® fit into your daily routine?”.2

References:

1. Braltus® Summary of Product Characteristics.
2. Braltus® In Real Life. November 2018, prepared by Branding Science.

t

Braltus® (tiotropium) Prescribing Information Request a placebo device

teva

Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva online, or tel: 0207 540 7117 or email: medinfo@tevauk.com.
Date of preparation: November 2022
Reference: Bral-GB-00141

Copyright © 2022 Teva UK Limited.
Registered in England No. 302461. Registered office: Teva UK Limited, Whistler Drive, Castleford, WF10 5HX 
+44 (0) 1977 628500 | www.tevauk.com | Contact Us

Teva Logo--100X35.png
Privacy Policy | Pharmacovigilance Privacy PolicyTerms and Conditions  | AccessibilityReporting Adverse Events